New Alzheimer's drug shows promise in early trial
NCT ID NCT06774261
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called phenserine in 16 people with early or mild Alzheimer's disease. The goal was to see how it affects brain cell health and inflammation compared to the standard drug donepezil. Participants took the drug for 8 weeks and had regular checkups. The study focused on safety and changes in biomarkers, not on curing the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stavanger University Hospital
Stavanger, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Could your brain help unlock Alzheimer's secrets?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a simple test predict Alzheimer's before symptoms worsen?
- Can a Voice-Based app map healthy brain aging across 80 years?